21.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics to host Esmo data update & third quarter earnings call on October 20, 2025 - MarketScreener
Summit Therapeutics To Host Esmo Data Update & Third Quarter Earnings Call On October 20, 2025 - TradingView
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 - Business Wire
Summit Therapeutics Inc. stock momentum explainedQuarterly Earnings Report & Expert Curated Trade Ideas - newser.com
News impact scoring models applied to Summit Therapeutics Inc.Quarterly Trade Summary & Trade Opportunity Analysis Reports - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Will Summit Therapeutics Inc. stock continue dividend increasesQuarterly Risk Review & Real-Time Buy Zone Alerts - newser.com
Can Summit Therapeutics Inc. hit a new high this monthBuy Signal & Accurate Entry/Exit Alerts - newser.com
Statistical indicators supporting Summit Therapeutics Inc.’s strengthBear Alert & Growth Focused Investment Plans - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
What drives Summit Therapeutics Inc stock priceSector Performance Drivers & Rapid Capital Portfolio - earlytimes.in
APEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Automated trading signals detected on Summit Therapeutics Inc.IPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
Summit Therapeutics stock reaffirmed Buy at UBS ahead of ESMO data - Investing.com
Has Summit Therapeutics Inc. formed a bullish divergenceWeekly Investment Recap & Consistent Return Investment Signals - newser.com
Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success - TipRanks
Is Summit Therapeutics Inc. stock supported by strong cash flowsGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
Summit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance
Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Stock Analysis: Unveiling a 51.75% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
Published on: 2025-10-05 07:31:28 - newser.com
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo
Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Published on: 2025-09-30 03:00:28 - newser.com
Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize
Published on: 2025-09-30 00:09:58 - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):